New Editorial Published in Frontiers in Molecular Biosciences
Dr. Qingyu Luo and Dr. Lin Zhang have coauthored a new editorial article highlighting the critical importance of bridging big data-based biomedical research with real-world cancer management.
PRESS RELEASES
One Patient One Cure
5/22/20252 min read
Qingyu Luo, MD, PhD, President of One Patient One Cure, and Lin Zhang, MD, PhD, FRSPH, Advisory Board member of One Patient One Cure, have coauthored an editorial article published in Frontiers in Molecular Biosciences, titled “Bridging Discovery and Translation in Novel Biomarkers and Big Data-Based Biomedical Studies for Cancer Management.”
In this article, Dr. Luo and Dr. Zhang highlight key discoveries from a special research topic they co-edited, showcasing advances in biomarker identification and big data-driven approaches to cancer diagnosis and treatment. Their editorial underscores the importance of translating biomedical research into clinical applications to enhance precision cancer care.
The research topic “Novel Biomarkers and Big Data-Based Biomedical Studies in Cancer Diagnosis and Management,” published in Frontiers in Molecular Biosciences, features 21 cutting-edge papers released in 2023 and 2024. These studies harness computational tools and AI-driven models to identify biomarkers that can predict cancer prognosis, treatment response, and potential side effects. By integrating clinical data with advanced analytics, this interdisciplinary effort aims to accelerate the translation of molecular discoveries into real-world clinical applications, advancing the promise of precision oncology.
Authored by over 150 researchers from countries including the United States, China, India, Australia, Sweden, Colombia, the United Arab Emirates, and the Republic of Korea, the collection has already achieved over 73,000 views and downloads—underscoring both its global impact and the urgent demand for data-driven innovations in cancer management.
Dr. Qingyu Luo emphasized the urgent need to bridge the gap between big data research and real-world clinical practice in a recent LinkedIn post. “We’ve been in the era of big data for more than a decade, and researchers have generated an abundance of publicly available datasets,” he wrote. “Yet, real-world cancer care remains largely confined to improving conventional chemotherapies—approaches that originated nearly a century ago—offering most patients one-size-fits-all regimens that rarely result in a cure.”
He also expressed pride and optimism in the mission of One Patient One Cure to deliver truly personalized, patient-centered cancer care on a global scale: “Now is the time to begin a new chapter in cancer management: one that translates the wealth of big data research into tangible patient benefit, and shifts the focus from drug-centered to patient-centered precision medicine. I am incredibly proud that One Patient One Cure is leading this initiative.”
https://www.linkedin.com/feed/update/urn:li:activity:7331321228223262720/